<DOC>
	<DOCNO>NCT01072734</DOCNO>
	<brief_summary>Annual influenza vaccination recommend patient systemic lupus erythematosus ( SLE ) . However concern remain vaccination risk lupus flare</brief_summary>
	<brief_title>Auto-immunity Lupus Patients After Influenza Vaccine</brief_title>
	<detailed_description>SLE chronic autoimmune disease associate production pathogenic anti-nuclear autoantibody ( ANAs ) characterize loss self tolerance overexpression B cell , lead high immunoglobulin production , 90 % autoantibody . There concern safety vaccination patient autoimmune disease hypothesise stimulation immune system via vaccination may lead increase disease activity . Furthermore , SLE patient display variety immune dysfunction may influence response influenza vaccination . Studies indicate , although influenza vaccination SLE may generate autoimmune phenomenon , clinically significant increase SLE disease activity expect . Therefore , influenza vaccination consider safe quiescent SLE , accordance previous review subject The aim study evaluate level CXCR4 leucocytes patient SLE could good prognostic marker efficacy safety influenza vaccine SLE patient . For purpose , assay lupus patient cellular level CXCR4 administration influenza vaccine correlate expression level CXCR4 : 1 ) evolution clinical biological sign autoimmunity 2 ) humoral immune response towards influenza . If influenza vaccine associate far increase risk lupus flare , important determine patient elevate leucocyte level CXCR4 , ( due impact molecule humoral immunity ) , risk vaccine side effect particularly autoimmune origin .</detailed_description>
	<mesh_term>Influenza , Human</mesh_term>
	<mesh_term>Lupus Erythematosus , Systemic</mesh_term>
	<mesh_term>Autoimmune Diseases</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>Inclusion criterion : 18 year age old informed consent sign LES patient meet American College Rheumatology ( ACR ) diagnostic criterion SLE Patient able attend visit schedule month follow influenza vaccine administration Clinical examination perform prior final inclusion result communicate patient Exclusion criterion : For woman , pregnant positive pregnancy test Positive HCV , HIV HBV Patient treat rituximab ( antiCD20 ) stop less year . Patient treatment majorization suspect within month follow influenza vaccine administration . Hypersensitivity active substance , egg one vaccine components Other vaccination within last 30 day inclusion J0 Administration blood product immunoglobulins within last 90 day J0 Progressive cancer , cirrhoses Acute severe illness within last 30 day inclusion J0 Patient non affiliate health social security system Planned participation another clinical study present study period patient deprive freedom administrative court order</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2010</verification_date>
	<keyword>Lupus</keyword>
	<keyword>CXCR4 leucocytes patient SLE</keyword>
	<keyword>Influenza vaccine</keyword>
</DOC>